Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 9258937 | 12 pages | https://doi.org/10.1155/2017/9258937

Apocynin Prevents Abnormal Megakaryopoiesis and Platelet Activation Induced by Chronic Stress

Academic Editor: Jeannette Vasquez-Vivar
Received03 Jul 2017
Accepted24 Sep 2017
Published28 Nov 2017

Abstract

Environmental chronic stress (ECS) has been identified as a trigger of acute coronary syndromes (ACS). Changes in redox balance, enhanced reactive oxygen species (ROS) production, and platelet hyperreactivity were detected in both ECS and ACS. However, the mechanisms by which ECS predisposes to thrombosis are not fully understood. Here, we investigated the impact of ECS on platelet activation and megakaryopoiesis in mice and the effect of Apocynin in this experimental setting. ECS induced by 4 days of forced swimming stress (FSS) treatment predisposed to arterial thrombosis and increased oxidative stress (e.g., plasma malondialdehyde levels). Interestingly, Apocynin treatment prevented these alterations. In addition, FSS induced abnormal megakaryopoiesis increasing the number and the maturation state of bone marrow megakaryocytes (MKs) and affecting circulating platelets. In particular, a higher number of large and reticulated platelets with marked functional activation were detected after FSS. Apocynin decreased the total MK number and prevented their ability to generate ROS without affecting the percentage of CD42d+ cells, and it reduced the platelet hyperactivation in stressed mice. In conclusion, Apocynin restores the physiological megakaryopoiesis and platelet behavior, preventing the detrimental effect of chronic stress on thrombosis, suggesting its potential use in the occurrence of thrombosis associated with ECS.

1. Introduction

Thrombosis is a pathological event, which can affect both veins and arteries, whose clinical manifestation is associated with deep vein thrombosis, myocardial infarction, cerebral stroke, and pulmonary embolism. A number of studies have shown a strong link between cardiovascular disease and psychological stress. Thus, psychological stress has been recently included as risk factor for cardiovascular disease [13]. In particular, psychological/environmental stress, inducing hyperactivation of platelets and coagulation factors and modifying the normal fibrinolytic processes, triggers a hypercoagulable state [4], predisposing to cardiovascular disease.

Interestingly, modifications in the redox balance and in the reactive oxygen species (ROS) production and alterations of genes regulating antioxidant systems, including NADPH oxidase, occur in both chronic stress and cardiovascular disease [59].

Several studies showed that endothelial cells, leukocytes, vascular smooth muscle cells, fibroblasts, and platelets are important sources of ROS after vascular injury and that these ROS can regulate platelet activation [10, 11], triggering a vicious circle that leads to thrombosis. However, the mechanisms by which chronic environmental stress predisposes to thrombosis and thereby to cardiovascular disease are not fully understood.

Therapeutic approaches targeting ROS production to reduce atherothrombotic risk and to prevent neurodegenerative diseases are developing [1214]. One of the most promising antioxidant drugs in experimental models is Apocynin (4-hydroxy-3-methoxyacetophenone) [15]. Apocynin is an active principle with anti-inflammatory properties [16] isolated from the root of the medicinal plant Picrorhiza Kurroa (Scrophulariaceae) [17]. Apocynin affects ROS generation inhibiting NADPH oxidase enzyme activation, and it turns out to be a scavenger of hydrogen peroxide [15, 18].

In this study, we aimed at evaluating the beneficial effect(s), if any, of Apocynin in preventing thrombosis induced by chronic psychological/behavioral stress and at exploring the underlying mechanism(s).

2. Methods

2.1. Ethics Statement and Experimental Design

The experimental groups consisted of FVB male mice (12–14 weeks old) supplied by Charles River and housed in a temperature-controlled, 12 h light/dark cycle environment with ad libitum access to water and fed on standard pellet diet. All experiments were approved by the National Ministry of Health-University of Milan Committee and of DGSA. Surgical procedures were performed in mice anesthetized with ketamine chlorhydrate (75 mg/kg; Intervet) and medetomidine (1 mg/kg; Virbac). Mice were randomized in different groups. Apocynin (Sigma-Aldrich; 15 mg/kg) or dimethylsulfoxide (DMSO) was intraperitoneally (i.p.) injected 1 h before start the first session of stress [8] and then added to the drinking water (300 mg/kg) for 5 days [19], corresponding to 2.4 mg/ml since our mice approximately drink 3–3.5 ml water/day. No side effects were reported during long time treatment (2–16 weeks) with Apocynin [19, 20]. The chronic forced swim stress (FSS) was performed as previously described [8]. Briefly, mice were individually placed in a 2000 ml glass beaker (height, 24 cm; diameter, 12 cm) filled with 1500 ml of room temperature water for 5 min twice a day for 4 consecutive days. Mice were then quickly dried with a towel and returned to their home cage. This model of stress is based on the well-established finding that repeated exposure to an inescapable stress, for which no active coping responses are available, induces depressive- and anxious-like behaviors in mice [2123]. Interestingly, this model of stress is considered a chronic model because behavioral alterations are chronically maintained for more than 4 weeks [2426]. Experiments were performed, and tissue, were collected 18 h after the last section of FSS (Figure 1).

Blood was collected into 3.8% sodium citrate (1 : 10 vol:vol) from anesthetized mice at time indicated. For plasma preparation, citrated blood was centrifuged at 3000 rpm for 20 min at 4°C to obtain plasma, which was immediately stored at −80°C until further analysis.

2.2. Whole Blood Counts

Blood was collected into sodium citrate from anesthetized mice by cardiac venipuncture, and the differential white blood cell and platelet count were performed on a Beckman Coulter AU480.

2.3. Rotational Thromboelastometry

Rotational Thromboelastography (ROTEM®) was used to measure coagulability in whole blood as previously described [27]. Briefly, citrated whole blood was added to a cuvette containing star-tem® solution or fib-tem® solution, and recording was started immediately and was allowed to proceed for 60 min according to the manufacturer’s instructions. Clotting characteristics were analysed in terms of clotting time (CT, time necessary for the formation of a clot with a diameter of 2 mm) and clot formation time (CFT, kinetic of a stable clot formation by activated platelets and fibrin) and maximum clot firmness and maximum clot elasticity (MCF and MCE, measure of the consistence and elasticity of the clot, resp.) were collected.

2.4. Malondialdhyde and NADPH/NADP Analyses

Malondialdhyde (Cat. MBS269473) and NADPH/NADP (Cat. MBS169276) were measured in plasma and bone marrow, respectively, by ELISA kit (MyBioSource) according the to manufacturer’s instructions.

2.5. Arterial Thrombosis Model

Experimental arterial thrombosis was induced as previously described [28]. The left carotid artery of anesthetized mice was dissected free and placed in the probe (model 0.7V, Transonic System) connected to transonic flow meter (Transonic T106). After blood flow stabilization (baseline flow constant for 7 min at least 0.8 ml/sec), a 1 × 1 mm strip of filter paper (Whatman N°1) soaked with FeCl3 (10% solution; Sigma-Aldrich) was applied over the carotid artery. After 3 min, the filter paper was removed, the carotid artery was washed with PBS, and the flow was recorded for 30 min. An occlusion was considered to be total and stable when the flow was reduced by >90% from baseline until the 30-minute observation time, with the flow during this period not changing by more than 1% from baseline per second.

2.6. Platelet–Leukocyte Aggregate Analysis

Platelet/monocyte and platelet/neutrophil aggregates were analysed as previously described [29]. Briefly, citrated blood was stimulated where indicated with ADP for 5 minutes and red blood cells were lysed by FACS Lysing solution (BD Biosciences); samples were stained with the anti-CD45, anti-CD41, and anti-CD14 or anti-Lys6G (eBiolegend, Cat. 103101, 133901, 150101, and 127601, resp.) and analysed by flow FACS “Novocyte 3000.” A minimum of 5000 events was collected in the CD14+ or Lys6G+ gate.

2.7. Platelet Studies

Washed platelets (WPs) were obtained from platelet-rich plasma (PRP), isolated following centrifugation at 100 for 10 min of citrated blood as previously described [30], with serial centrifugation and addition of 0.2 mM PGI2 and 0.01 mg/l apyrase. Platelet pellets were resuspended in HEPES-Tyrode’s buffer (137 mM NaCl, 20 mM HEPES, 5.6 mM glucose, 0.35% bovine serum, 1 mM MgCl2, 2.7 mM KCl, and 3.3 mM NaH2PO4).

25 μl of WPs (5 × 104/μl in HEPES-Tyrode’s buffer supplemented with 1 mM CaCl2) was mixed with a saturating concentration of PE-conjugated JON/A (Emfret Analytic, Cat. M023-2) antibody, raised against the activated form of GPIIbIIIa (αIIβΙII integrin), or with anti-CD62P and FITC-conjugated antibody (P-selectin; BD Biosciences, Cat. 553744), and the mixture reacted with different concentrations of ADP or thrombin for 15 minutes at room temperature. The reaction was stopped by 400 μl ice-cold PBS, and samples were analysed within 30 minutes. Platelets were identified by forward and side scatter distribution and by anti-CD41 positivity.

Reticulated platelets (RP) were identified by the thiazole orange method [30]: 10 μl of PRP was incubated with 390 μl of thiazole orange (Retic-Count; BD Biosciences) or PBS as control and anti-CD41 at room temperature for 10 minutes, in the dark.

Immediately after incubation, samples were analysed by flow cytometry collecting 10000 CD41-positive events; the percentage of RP was recorded, and the absolute number of RP was calculated by multiplying by the platelet count.

2.8. Megakaryocyte Analyses

For single-cell suspensions from bone marrow, BM was flushed in PBS (Ca2+- and Mg2+-free) containing 3% BSA, 5.5 mM D-glucose, 10.2 mM trisodium citrate, and 10 μM PGE1 were filtered through a sterile nylon mesh (70 μm) and centrifuged (5 min, 200). Cells were first resuspended in FACS Lysing solution to lyse red blood cells, then washed and resuspended in PBS plus 2% FBS, and stained for 20 minutes on ice with PE-conjugated CD41 (BD Biosciences, Cat. 558040) and FITC-conjugated CD61 (BD Biosciences, Cat. 561911) or FITC-conjugated CD42d (Emfret Analytics, Cat. M061-1). The percentage of CD41-positive (CD41+) and CD61-positive (CD61+) cells or of CD41-positive (CD41+) and CD42d-positive (CD42d+) cells was evaluated by FACS on a FITC gate, and PE was set at 1% on samples stained with the control antibody [30]. CD41+/CD61+ was used as marker of total megakaryocyte, and CD41+/CD42d+ as marker of mature megakaryocytes.

For ROS detection, single-cell suspensions from bone marrow were stained with PE-conjugated CD41 and incubated with 20 μM H2DCF-DA (2,7-dichlorodihydrofluorescein diacetate, Sigma-Aldrich) for 15 minutes at 37°C and 5% CO2, then samples were analysed by FACS. Live events were collected on the basis of side scatter plots. MKs were gated by identification of CD41-PE-positive cells [31].

Flow cytometry was performed on a flow FACS “Novocyte 3000,” collecting 3000 events per sample.

2.9. Bone Marrow Histology

Immunohistochemistry was performed on BM as previously described [30]. Tissues were fixed overnight in 4% formalin, embedded in paraffin, cut at 3 μm, and mounted on polarized slides. BM samples were decalcified in 10% EDTA, pH 8 for 10 days before paraffin embedding. Sections were stained in Hematoxylin and Eosin (H&E). Slides were dewaxed, rehydrated, washed in PBS containing 0.1% Triton X100 for 15 minutes, and treated with 3% H2O2 for 10 minutes to block endogenous peroxidase. Antigen retrieval was performed with 0.01 M citrate buffer (pH 6) in a water bath at 98°C for 10 or 30 minutes according to the antibody used. Slides were incubated overnight at 4°C with the following primary antibodies: anti-NOX1 polyclonal antibody (1 : 200, GeneTex, Cat. GTX103888) or with rabbit preimmune IgGs (Vector Laboratories, Cat. I-1000) as negative controls. For immunoperoxidase, biotinylated anti-rabbit secondary antibody (Dako, Glostrup, Denmark, Cat. E0432) and then streptavidin/HRP (Dako, Glostrup, Denmark, Cat. P0397) were used and developed with the DAB substrate kit (Sigma-Aldrich). Slides were lightly counterstained with hematoxylin and observed and digitalized by a Zeiss Axioskop (Carl Zeiss) equipped with an intensified charge-coupled device (CCD) camera system (Photometrics). The number and area of megakaryocytes were evaluated in hematoxylin and eosin stained sections by counting 5–7 40x microscopic fields for each tissue sample [32].

2.10. Statistical Analysis

Statistical analyses were performed with GraphPad Prism 6.0 and SAS versus 9.4 software (SASA Institute). Data were analyzed by one- or 2-way ANOVA with repeated measures for main effects of treatment and time or stimuli, followed by a Dunn’s test or a Bonferroni post hoc analysis as appropriate. Values of were considered statistically significant. Data are expressed as mean ± SEM. For each box-plot, the center line illustrates the median, and box limits indicate the 25th and 75th percentiles.

3. Results

3.1. Effect of Apocynin on Chronic Stress and Oxidative Stress

To assess whether the chronic forced swimming treatment for 4 days was sufficient to induce a stress-response, we weighted adrenal glands as an index of terminal phase of hypothalamic-pituitary-adrenal neuroendocrine system activation. As expected, adrenal gland weight was greater in the stressed group of mice compared to the control group (; Figure 2(a)). Apocynin treatment did not modify the adrenal gland hypertrophy induced by forced swimming stress (FSS; Figure 2(a)), suggesting that Apocynin does not change the physiological response to the stress protocol. No significant difference in spleen or body weight between control and stressed mice with or without Apocynin treatment was found (Figures 2(b) and 2(c)).

Next, we measured the plasma malondialdehyde (P-MDA) levels, as marker of oxidative stress. The P-MDA levels were higher in the FSS-group compared to the control (; Figure 2(d)). Interestingly, Apocynin administration restored the normal P-MDA levels in stressed mice (Figure 2(d)).

3.2. Apocynin Prevented Arterial Thrombosis Induced by Forced Swimming Stress (FSS)

FSS accelerated occlusion rates in FeCl3-injuried carotid arteries (Figure 3). In particular, FeCl3 application reduced dramatically the blood flow within 10 minutes and led to a stable occlusion in 100% of mice exposed to FSS, but it was unable to induce a stable occlusion in control mice within the same 30-minute observation period (Figure 3). In mice treated with Apocynin, blood flow was slightly but significantly reduced in the first 10 minutes after topical application of FeCl3 and remained constant over all the observation period (Figure 3). The total occlusion of carotid artery induced by FSS was completely prevented in all treated mice (Figure 3).

No significant difference in terms of basal levels of blood flow was noted between the animal groups (control: 0.616 ± 0.07 ml/min; FSS: 0.557 ± 0.10 ml/min and FSS + Apocynin: 0.543 ± 0.08 ml/min).

3.3. Effect of Forced Swimming Stress (FSS) on Blood Hemostasis

Thromboelastography analysis (ROTEM analyses) in whole blood provided evidence that FSS affected blood hemostasis by shortening the clotting formation time (CFT: control: 160.2 ± 10.39 sec and FSS: 90.67 ± 9.90 sec, ) and increasing the maximum clot firmness (MCF: control: 60.33 ± 1.76 mm and FSS: 67.83 ± 1.6 mm, ) and maximum clot elasticity (MCE: control: 154.5 ± 11.73 mm and FSS: 214.8 ± 16.27 mm, ). In contrast, similar coagulation time in na-tem test (CT: control: 293.7 ± 15.38 sec and FSS: 235.3 ± 25.19 sec, ) and comparable MCF in fib-tem test (MCF: control: 20.67 ± 1.91 mm and FSS: 23.50 ± 2.62 mm, ) were detected in control and FSS groups.

These data suggest that chronic stress did not affect coagulation pathway and fibrinogen but instead, it promoted hyperactivation of platelets.

3.4. Effect of Apocynin on Circulating Cell Number and Platelet Function in Response to Forced Swimming Stress (FSS)

As previously shown in mouse and human studies [3335], FSS increased the number of circulating leukocytes (Figure 4(a), ) and platelets (Figure 4(b), ) and enhanced platelet size (Figure 4(c), ) and the percentage of reticulated platelets (Figure 4(d), ). Apocynin reverted these changes in stressed mice toward the restoration of the physiological number of leukocyte and platelet shape (Figure 4).

Interestingly, activation of integrin αIIbβ3 (GPIIbIIIa) (Figure 5(a), ) as well as the expression of P-selectin on platelet surface (Figure 5(b), ) in response to different stimulus was higher in stressed mice compared to control. The greater expression of P-selectin went hand in hand with the enhanced percentage of platelet monocyte (Figure 5(c), ), platelet/neutrophil (Figure 5(d), ), or platelet/lymphocyte (Figure 5(e), ) aggregates in response to ADP.

Remarkably, the platelet hyperreactivity induced by FSS was completely prevented by Apocynin treatment (Figure 5).

3.5. Effect of Apocynin on Megakaryopoiesis in Stressed Mice

To assess whether the thrombocytosis consequent to FSS exposure was associated to the abnormal megakaryopoiesis, bone marrow megakaryocytes were analyzed.

Histopathological analysis of bone marrow section (Figure 6(a)) revealed a higher number of megakaryocytes (MKs) in stressed mice compared to control (FSS: 11.04 ± 0.28 MKs/field versus control: 7.93 ± 0.58 MKs/field, ; Figure 6(b)), and flow cytometer analyses showed that FSS increased significantly the percentage of CD41+/CD61+ cells in bone marrow (Figure 6(c), ). In addition, careful analyses of these sections revealed that megakaryocytes from stressed mice were larger (Figure 6(d), ) and displayed greater nuclear complexity (Figure 6(e)) compared to control. In particular, higher percentage of polylobulated megakaryocytes () and lower percentage of mononucleated () or binucleated () megakaryocytes were detected in bone marrow from stressed mice. The advanced maturation state of megakaryocytes from stressed mice suggested by morphological examination was sustained by the enhanced expression of lineage differentiation marker CD42d (Figure 6(f), ). Interestingly, Apocynin decreased markedly the number of megakaryocytes (), but only slightly reduced the total area, without affecting their maturation state.

Finally, we showed that FSS decreased the NADPH/NADP+ ratio (Figure 7(a)) and upregulated NOX1 expression in bone marrow, including megakaryocytes (Figure 7(b)). Interestingly, NOX1 is the most abundant NOX isoform in this type of cells [36]. In addition, FSS specifically induced reactive oxygen species (ROS) production in megakaryocytes (Figure 7(c), ). As expected, Apocynin restored the physiological NADPH/NADP+ ratio and markedly decreased ROS generation and NOX1 expression induced by FSS (Figure 7).

4. Discussion

In this study, we show that Apocynin treatment, by preventing ROS generation, restores the physiological megakaryopoiesis and platelet function and reduces arterial thrombosis. Overall, these findings suggest that ROS play a key role in the susceptibility to thrombosis induced by chronic psychological/behavioral stress, affecting the production/activation of megakaryocytes, with consequent increase of both number and reactivity of circulating platelets.

Chronic environmental/psychological stress increases the hypothalamic-pituitary-adrenal axis activation [37] and induces a dysregulation in norepinephrine system that turns a homeostatic stress response into a pathological stress response [38]. Then, the observation that chronic environmental stress accelerates norepinephrine-mediated hematopoiesis promoting atherosclerotic plaque features associated with vulnerable lesions [35] well explained the correlation between psychological stress and acute myocardial infarction emerged from the INTERHEART study [39]. However, chronic environmental stress increases the risk for cardiovascular disease also promoting a prothrombotic state [4042]. As a matter of fact, chronic stress increases the levels of tissue factor and of the plasminogen activation inhibitor-1 [4042] and the number of circulating platelets [33]. Interestingly, here, we showed that 5 minutes of “forced swimming stress” session, performed twice a day for 4 consecutive days, is sufficient to induce a greater and more stable clot and to predispose mice to arterial thrombosis, without affecting fibrinogen and coagulation factor activation in agreement with data obtained by other stress models, such as restraint or foot shock stress [40, 43]. In addition, stressed mice not only have a higher number of circulating cells (leukocytes and platelets) but also have bigger, reticulated, and hyperresponsive platelets as previously reported in human studies [35, 4446], which suggest modification in bone marrow milieu. Indeed, thrombopoiesis is a complex process resulting from many consecutive steps including proliferation and maturation of megakaryocytes [47]. Accordingly, we provide evidence that chronic stress increases the number of bone marrow megakaryocytes and it affects morphology as well. Megakaryocytes from stressed mice display an advanced maturation state, in terms of bigger size, greater nuclear complexity, and enhanced expression of CD42d antigen. In addition, megakaryocytes from stressed mice produce higher levels of ROS.

Previous studies have shown that both sympathetic transmitters (e.g., norepinephrine and epinephrine) and ROS promote proliferation of hematopoietic stem cells, their differentiation to megakaryocytes, and they induce megakaryocyte adhesion, migration, and proplatelet formation [33, 48]. Intriguingly, chronic stress increases norepinephrine levels in bone marrow [35], which in turn increases NADPH oxidase-derived superoxide in different type of cells [49, 50], suggesting a potential link between these cellular messengers under chronic stress condition. Moreover, we show that the NOX1 catalytic subunit, expressed in different type of cells, including macrophages, hematopoietic stem cells, and megakaryocytes [36, 51, 52], is upregulated by chronic stress in all bone marrow cells and not only in megakaryocytes.

Interestingly, previous experiments performed with different oxidase inhibitors suggest that the NADPH oxidase enzyme is the critical source of ROS in megakaryocytes [53] and that NADPH oxidase inhibition completely prevents the signaling cascade activation required for megakaryocyte differentiations [54], reducing their polyploidization [36]. However, the single deletion of NOX1 or of NOX2 alone, some of the subunits of NADPH oxidase, is not sufficient to modulate MK polyploidization [36] as provided by in vivo experiment, supporting the concept of a mutual compensation between the NOX isoforms.

Experimental and clinical data show that NADPH oxidase plays a key role also in platelet ROS generation and platelet activation [7, 5557].

In line with these findings, we show here for the first time that Apocynin treatment prevents the detrimental effect of chronic psychological/behavioral stress, affecting production of ROS and leading to thrombosis, throughout the regulation of megakaryopoiesis and platelet activation.

In particular, the strong effect of Apocynin in the prevention of prothrombotic phenotype promoted by environmental stress may be the result of a pleiotropic effect of this compound on different cells and tissues (e.g., megakaryocytes, bone marrow milieu, platelets, and vessel walls). Indeed, the higher levels of NOX1 expression induced by chronic stress in bone marrow cells, including also megakaryocytes, are significantly reduced by Apocynin treatment. In addition, Apocynin prevents platelet activation and improves endothelial/vascular function [58, 59] reducing ROS by preventing their generation by the binding of NOXO1 and p47phox to p22phox and/or decreasing Rho kinases activity [60] and acting as radical scavenger [18]. However, Apocynin may affect platelet function also by a mechanism different from the abovementioned, which has not been well identified [61]. In particular, it is demonstrated that Apocynin might indirectly inhibit NADPH oxidase activity depleting its catalytic substrates such as NADPH [62] and decreasing the intracellular reduce/oxidase GSH/GSSG ratio [63].

5. Conclusion

Our data not only provide new important knowledge about the mechanisms by which chronic stress affects arterial thrombosis but also suggest that Apocynin is useful in the prevention of thrombosis associated to chronic environmental stress.

Disclosure

A part of this manuscript had been presented as a meeting abstract (Arteriosclerosis, Thrombosis, and Vascular Biology. 2017; 37: A29).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to thank Dr. Elisa Turra for the technical immunohistochemistry support. The present work was supported by the Italian Ministry of Health (Ricerca Corrente: BIO33-2013, ID: 2600692; BIO33-2014, ID: 2607452; BIO33-2015, ID: 2622789; BIO37-2016, ID: 2613074; BIO37-2017, ID: 2631213). Cofunding was provided by the contribution of the Italian “5 × 1000” tax (2013 and 2014).

References

  1. D. S. Krantz, D. S. Sheps, R. M. Carney, and B. H. Natelson, “Effects of mental stress in patients with coronary artery disease: evidence and clinical implications,” JAMA, vol. 283, no. 14, pp. 1800–1802, 2000. View at: Publisher Site | Google Scholar
  2. M. A. Mittleman, M. Maclure, J. B. Sherwood et al., “Triggering of acute myocardial infarction onset by episodes of anger. Determinants of myocardial infarction onset study investigators,” Circulation, vol. 92, no. 7, pp. 1720–1725, 1995. View at: Publisher Site | Google Scholar
  3. A. Steptoe and M. Kivimaki, “Stress and cardiovascular disease,” Nature Reviews. Cardiology, vol. 9, no. 6, pp. 360–370, 2012. View at: Publisher Site | Google Scholar
  4. R. von Kanel, P. J. Mills, C. Fainman, and J. E. Dimsdale, “Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease?” Psychosomatic Medicine, vol. 63, no. 4, pp. 531–544, 2001. View at: Publisher Site | Google Scholar
  5. J. A. Leopold and J. Loscalzo, “Oxidative risk for atherothrombotic cardiovascular disease,” Free Radical Biology & Medicine, vol. 47, no. 12, pp. 1673–1706, 2009. View at: Publisher Site | Google Scholar
  6. D. Pietraforte, R. Vona, A. Marchesi et al., “Redox control of platelet functions in physiology and pathophysiology,” Antioxidants & Redox Signaling, vol. 21, no. 1, pp. 177–193, 2014. View at: Publisher Site | Google Scholar
  7. A. J. Begonja, S. Gambaryan, J. Geiger et al., “Platelet NAD(P)H-oxidase-generated ROS production regulates αIIbβ3-integrin activation independent of the NO/cGMP pathway,” Blood, vol. 106, no. 8, pp. 2757–2760, 2005. View at: Publisher Site | Google Scholar
  8. J. S. Seo, J. Y. Park, J. Choi et al., “NADPH oxidase mediates depressive behavior induced by chronic stress in mice,” The Journal of Neuroscience, vol. 32, no. 28, pp. 9690–9699, 2012. View at: Publisher Site | Google Scholar
  9. P. Wenzel, S. Kossmann, T. Munzel, and A. Daiber, “Redox regulation of cardiovascular inflammation - immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species,” Free Radical Biology & Medicine, vol. 109, pp. 48–60, 2017. View at: Publisher Site | Google Scholar
  10. F. Jiang, Y. Zhang, and G. J. Dusting, “NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair,” Pharmacological Reviews, vol. 63, no. 1, pp. 218–242, 2011. View at: Publisher Site | Google Scholar
  11. F. Violi and P. Pignatelli, “Platelet oxidative stress and thrombosis,” Thrombosis Research, vol. 129, no. 3, pp. 378–381, 2012. View at: Publisher Site | Google Scholar
  12. N. Panth, K. R. Paudel, and K. Parajuli, “Reactive oxygen species: a key Hallmark of cardiovascular disease,” Advances in Medicine, vol. 2016, Article ID 9152732, 12 pages, 2016. View at: Publisher Site | Google Scholar
  13. M. Patel, “Targeting oxidative stress in central nervous system disorders,” Trends in Pharmacological Sciences, vol. 37, no. 9, pp. 768–778, 2016. View at: Publisher Site | Google Scholar
  14. S. Schiavone and L. Trabace, “Pharmacological targeting of redox regulation systems as new therapeutic approach for psychiatric disorders: a literature overview,” Pharmacological Research, vol. 107, pp. 195–204, 2016. View at: Publisher Site | Google Scholar
  15. S. Heumuller, S. Wind, E. Barbosa-Sicard et al., “Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant,” Hypertension, vol. 51, no. 2, pp. 211–217, 2008. View at: Publisher Site | Google Scholar
  16. F. Engels, B. F. Renirie, B. A. Hart, R. P. Labadie, and F. P. Nijkamp, “Effects of apocynin, a drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism,” FEBS Letters, vol. 305, no. 3, pp. 254–256, 1992. View at: Publisher Site | Google Scholar
  17. J. M. Simons, L. A. Hart, H. van Dijk, F. C. Fischer, K. T. de Silva, and R. P. Labadie, “Immunodulatory compounds from Picrorhiza kurroa: isolation and characterization of two anti-complementary polymeric fractions from an aqueous root extract,” Journal of Ethnopharmacology, vol. 26, no. 2, pp. 169–182, 1989. View at: Publisher Site | Google Scholar
  18. M. S. Petronio, M. L. Zeraik, L. M. Fonseca, and V. F. Ximenes, “Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor,” Molecules, vol. 18, no. 3, pp. 2821–2839, 2013. View at: Publisher Site | Google Scholar
  19. K. A. Trumbull, D. McAllister, M. M. Gandelman et al., “Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice,” Neurobiology of Disease, vol. 45, no. 1, pp. 137–144, 2012. View at: Publisher Site | Google Scholar
  20. M. Dumont, C. Stack, C. Elipenhali, N. Y. Calingasan, E. Wille, and M. F. Beal, “Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer’s disease,” Neuroscience Letters, vol. 492, no. 3, pp. 150–154, 2011. View at: Publisher Site | Google Scholar
  21. E. A. Stone, M. L. Lehmann, Y. Lin, and D. Quartermain, “Reduced evoked fos expression in activity-related brain regions in animal models of behavioral depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 6, pp. 1196–1207, 2007. View at: Publisher Site | Google Scholar
  22. E. A. Stone and Y. Lin, “Open-space forced swim model of depression for mice,” Current Protocols in Neuroscience, Chapter 9, p. 36, 2011. View at: Publisher Site | Google Scholar
  23. E. A. Stone, Y. Lin, and D. Quartermain, “Evaluation of the repeated open-space swim model of depression in the mouse,” Pharmacology, Biochemistry, and Behavior, vol. 91, no. 1, pp. 190–195, 2008. View at: Publisher Site | Google Scholar
  24. E. Meshorer, B. Bryk, D. Toiber et al., “SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA,” Molecular Psychiatry, vol. 10, no. 11, pp. 985–997, 2005. View at: Publisher Site | Google Scholar
  25. B. S. Sailaja, D. Cohen-Carmon, G. Zimmerman, H. Soreq, and E. Meshorer, “Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 52, pp. E3687–E3695, 2012. View at: Publisher Site | Google Scholar
  26. T. Serchov, H. W. Clement, M. K. Schwarz et al., “Increased signaling via adenosine A1 receptors, sleep deprivation, imipramine, and ketamine inhibit depressive-like behavior via induction of Homer1a,” Neuron, vol. 87, no. 3, pp. 549–562, 2015. View at: Publisher Site | Google Scholar
  27. P. Amadio, G. I. Colombo, E. Tarantino et al., “BDNFVal66met polymorphism: a potential bridge between depression and thrombosis,” European Heart Journal, vol. 38, no. 18, pp. 1426–1435, 2017. View at: Publisher Site | Google Scholar
  28. F. Bonacina, S. S. Barbieri, L. Cutuli et al., “Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1862, no. 6, pp. 1182–1190, 2016. View at: Publisher Site | Google Scholar
  29. P. Amadio, E. Tarantino, L. Sandrini, E. Tremoli, and S. S. Barbieri, “Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice,” Thrombosis and Haemostasis, vol. 117, no. 8, pp. 1486–1497, 2017. View at: Publisher Site | Google Scholar
  30. S. S. Barbieri, G. Petrucci, E. Tarantino et al., “Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice,” Thrombosis and Haemostasis, vol. 114, no. 6, pp. 1218–1229, 2015. View at: Publisher Site | Google Scholar
  31. S. S. Barbieri, P. Amadio, S. Gianellini, E. Zacchi, B. B. Weksler, and E. Tremoli, “Tobacco smoke regulates the expression and activity of microsomal prostaglandin E synthase-1: role of prostacyclin and NADPH-oxidase,” The FASEB Journal, vol. 25, no. 10, pp. 3731–3740, 2011. View at: Publisher Site | Google Scholar
  32. M. Trakala, D. Partida, M. Salazar-Roa et al., “Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice,” Blood, vol. 126, no. 14, pp. 1707–1714, 2015. View at: Publisher Site | Google Scholar
  33. S. Chen, C. Du, M. Shen et al., “Sympathetic stimulation facilitates thrombopoiesis by promoting megakaryocyte adhesion, migration, and proplatelet formation,” Blood, vol. 127, no. 8, pp. 1024–1035, 2016. View at: Publisher Site | Google Scholar
  34. C. Giannarelli, D. T. Rodriguez, M. U. Zafar et al., “Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation,” Thrombosis and Haemostasis, vol. 117, no. 4, pp. 816–818, 2017. View at: Publisher Site | Google Scholar
  35. T. Heidt, H. B. Sager, G. Courties et al., “Chronic variable stress activates hematopoietic stem cells,” Nature Medicine, vol. 20, no. 7, pp. 754–758, 2014. View at: Publisher Site | Google Scholar
  36. D. J. McCrann, A. Eliades, M. Makitalo, K. Matsuno, and K. Ravid, “Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidy,” Blood, vol. 114, no. 6, pp. 1243–1249, 2009. View at: Publisher Site | Google Scholar
  37. B. S. McEwen, “Physiology and neurobiology of stress and adaptation: central role of the brain,” Physiological Reviews, vol. 87, no. 3, pp. 873–904, 2007. View at: Publisher Site | Google Scholar
  38. A. W. Goddard, S. G. Ball, J. Martinez et al., “Current perspectives of the roles of the central norepinephrine system in anxiety and depression,” Depression and Anxiety, vol. 27, no. 4, pp. 339–350, 2010. View at: Publisher Site | Google Scholar
  39. A. Rosengren, S. Hawken, S. Ounpuu et al., “Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study,” Lancet, vol. 364, no. 9438, pp. 953–962, 2004. View at: Publisher Site | Google Scholar
  40. S. F. Stampfli, G. G. Camici, S. Keller et al., “Restraint stress enhances arterial thrombosis in vivo - role of the sympathetic nervous system,” Stress, vol. 17, no. 1, pp. 126–132, 2014. View at: Publisher Site | Google Scholar
  41. Y. Uchida, K. Takeshita, K. Yamamoto et al., “Stress augments insulin resistance and prothrombotic state: role of visceral adipose-derived monocyte chemoattractant protein-1,” Diabetes, vol. 61, no. 6, pp. 1552–1561, 2012. View at: Publisher Site | Google Scholar
  42. K. Yamamoto, T. Shimokawa, H. Yi et al., “Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse,” Blood, vol. 100, no. 12, pp. 4011–4018, 2002. View at: Publisher Site | Google Scholar
  43. T. Dong, Y. W. Cheng, F. Yang et al., “Chronic stress facilitates the development of deep venous thrombosis,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 384535, 8 pages, 2015. View at: Publisher Site | Google Scholar
  44. P. Hjemdahl, P. T. Larsson, and N. H. Wallen, “Effects of stress and beta-blockade on platelet function,” Circulation, vol. 84, 6 Supplement, pp. VI44–VI61, 1991. View at: Google Scholar
  45. P. T. Larsson, P. Hjemdahl, G. Olsson, N. Egberg, and G. Hornstra, “Altered platelet function during mental stress and adrenaline infusion in humans: evidence for an increased aggregability in vivo as measured by filtragometry,” Clinical Science, vol. 76, no. 4, pp. 369–376, 1989. View at: Publisher Site | Google Scholar
  46. S. M. Patterson, D. S. Krantz, J. S. Gottdiener, G. Hecht, S. Vargot, and D. S. Goldstein, “Prothrombotic effects of environmental stress: changes in platelet function, hematocrit, and total plasma protein,” Psychosomatic Medicine, vol. 57, no. 6, pp. 592–599, 1995. View at: Publisher Site | Google Scholar
  47. J. C. Kostyak, M. U. Naik, and U. P. Naik, “Calcium- and integrin-binding protein 1 regulates megakaryocyte ploidy, adhesion, and migration,” Blood, vol. 119, no. 3, pp. 838–846, 2012. View at: Publisher Site | Google Scholar
  48. Y. F. Wang, C. H. Tsai, Y. T. Huang et al., “Size distribution of airborne fungi in vehicles under various driving conditions,” Archives of Environmental & Occupational Health, vol. 68, no. 2, pp. 95–100, 2013. View at: Publisher Site | Google Scholar
  49. S. H. Deo, N. T. Jenkins, J. Padilla, A. R. Parrish, and P. J. Fadel, “Norepinephrine increases NADPH oxidase-derived superoxide in human peripheral blood mononuclear cells via α-adrenergic receptors,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 305, no. 10, pp. R1124–R1132, 2013. View at: Publisher Site | Google Scholar
  50. F. Xiong, D. Xiao, and L. Zhang, “Norepinephrine causes epigenetic repression of PKCε gene in rodent hearts by activating Nox1-dependent reactive oxygen species production,” The FASEB Journal, vol. 26, no. 7, pp. 2753–2763, 2012. View at: Publisher Site | Google Scholar
  51. M. Gimenez, B. M. Schickling, L. R. Lopes, and F. J. Miller Jr., “Nox1 in cardiovascular diseases: regulation and pathophysiology,” Clinical Science, vol. 130, no. 3, pp. 151–165, 2016. View at: Publisher Site | Google Scholar
  52. C. Piccoli, A. D'Aprile, M. Ripoli et al., “Bone-marrow derived hematopoietic stem/progenitor cells express multiple isoforms of NADPH oxidase and produce constitutively reactive oxygen species,” Biochemical and Biophysical Research Communications, vol. 353, no. 4, pp. 965–972, 2007. View at: Publisher Site | Google Scholar
  53. C. Prata, T. Maraldi, L. Zambonin, D. Fiorentini, G. Hakim, and L. Landi, “ROS production and Glut1 activity in two human megakaryocytic cell lines,” BioFactors, vol. 20, no. 4, pp. 237–247, 2004. View at: Publisher Site | Google Scholar
  54. J. L. Sardina, G. Lopez-Ruano, L. I. Sanchez-Abarca et al., “p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation,” Cell Death and Differentiation, vol. 17, no. 12, pp. 1842–1854, 2010. View at: Publisher Site | Google Scholar
  55. R. Carnevale, L. Loffredo, C. Nocella et al., “Impaired platelet activation in patients with hereditary deficiency of p47phox,” British Journal of Haematology, 2016. View at: Publisher Site | Google Scholar
  56. S. Chlopicki, R. Olszanecki, M. Janiszewski, F. R. M. Laurindo, T. Panz, and J. Miedzobrodzki, “Functional role of NADPH oxidase in activation of platelets,” Antioxidants & Redox Signaling, vol. 6, no. 4, pp. 691–698, 2004. View at: Publisher Site | Google Scholar
  57. K. Y. Stokes, J. M. Russell, M. H. Jennings, J. S. Alexander, and D. N. Granger, “Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia,” Free Radical Biology & Medicine, vol. 43, no. 1, pp. 22–30, 2007. View at: Publisher Site | Google Scholar
  58. D. Pastori, P. Pignatelli, R. Carnevale, and F. Violi, “Nox-2 up-regulation and platelet activation: novel insights,” Prostaglandins & Other Lipid Mediators, vol. 120, pp. 50–55, 2015. View at: Publisher Site | Google Scholar
  59. A. Virdis, M. Gesi, and S. Taddei, “Impact of apocynin on vascular disease in hypertension,” Vascular Pharmacology, vol. 87, pp. 1–5, 2016. View at: Publisher Site | Google Scholar
  60. T. Maraldi, “Natural compounds as modulators of NADPH oxidases,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 271602, 10 pages, 2013. View at: Publisher Site | Google Scholar
  61. J. Dharmarajah, J. F. Arthur, C. G. Sobey, and G. R. Drummond, “The anti-platelet effects of apocynin in mice are not mediated by inhibition of NADPH oxidase activity,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 382, no. 4, pp. 377–384, 2010. View at: Publisher Site | Google Scholar
  62. G. Galati, O. Sabzevari, J. X. Wilson, and P. J. O'Brien, “Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics,” Toxicology, vol. 177, no. 1, pp. 91–104, 2002. View at: Publisher Site | Google Scholar
  63. S. S. Barbieri, V. Cavalca, S. Eligini et al., “Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms,” Free Radical Biology & Medicine, vol. 37, no. 2, pp. 156–165, 2004. View at: Publisher Site | Google Scholar

Copyright © 2017 Leonardo Sandrini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1024 Views | 314 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.